We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gyg Plc | LSE:GYG | London | Ordinary Share | GB00BZ4FM652 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 30.00 | 25.00 | 45.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
17/11/2004 07:48 | Are you watching HCEG? | zapa | |
11/11/2004 12:55 | off topic but keep an eye on HCEG. | zapa | |
04/11/2004 15:23 | RNS Number:8722E Gyrus Group PLC 04 November 2004 GYRUS GROUP PLC ("Gyrus" or "the Company") Notification of Interests of Directors and Connected Persons The Company has been advised that Dr C Goodson-Wickes, non-executive director, purchased 4,150 shares at 235.19p on 2nd November 2004. His total resultant share holding following this notification has increased to 6,586 (0.008%) of the issued share capital of the company. | johnroger | |
22/10/2004 12:59 | Oh yer thanks. Its a good deal, a profitable business that can be improved and it'll help Gyrus capture more of the market and also re-address the dollar imbalance. On the director selling - The Chairman Brian Steer has exercised 75k options and held onto 53k of them which means he's had to shell out himself - over £30k plus to retain them so that's a bullish sign. Still, neither of these do it for me - perhaps your right and there's a rumour of a bidder? Regards, Maddox | maddox | |
22/10/2004 11:45 | 7th November 2003 - Gyrus announces acquisition of Explorent GmbH for up to Euro 5.5 million Gyrus Group announces the acquisition of Explorent GmbH, a sourcing and distribution business for surgical instruments used in Ear, Nose and Throat (ENT) surgery, for up to Euro 5.5 million in cash. Based in Tuttlingen, Germany, Explorent sells its branded products throughout the world via distribution partners. The acquisition provides Gyrus with a platform from which to grow its German business and develop its own source of reusable surgical instruments similar to those currently purchased from third parties. For the year to 31st December 2002, Explorent had revenues of approximately Euro 5.5 million and profit before tax of approximately Euro 891,000. Net assets at 31st December 2002 amounted to Euro 1.2 million. Gyrus is paying Euro 5.0 million on completion and up to Euro 0.5 million by 31st October 2004. The acquisition of Explorent is a further step in the development of the Group's international strategy and follows the recent acquisition of Entermed B.V. in September 2003. Entermed B.V. currently distributes Gyrus's range of ENT products within a broader product portfolio, including Explorent's surgical instrument range, to surgeons in Benelux. Commenting on the acquisition, Brian Steer, Executive Chairman of Gyrus, said today "The acquisition of Explorent represents both an expansion for Gyrus into the growing ENT market in Germany and an opportunity to gain cost efficiencies in our sourcing of surgical instruments for the important world-wide ENT market." Its slipped your mind. | zapa | |
22/10/2004 11:37 | Hi Zapa, What's the explorent deal? Regards, David | maddox | |
22/10/2004 11:08 | The Explorent deal is finalised on the 31st. | zapa | |
22/10/2004 10:08 | A buyer in the wings? But even that dosent make real sence as we had the selling by the director and further selling by one of the institutions. Chloride is doing the opposite. | zapa | |
22/10/2004 10:00 | Nice 11p rise to 242p yesterday. Looking at the trades there were overall more sold than bought so its difficult to understand the rise? Anyone care to venture an interpretation for this apparent anomaly? Regards, Maddox | maddox | |
11/10/2004 10:38 | Pachiaammos, I would certainly suggest that they consider it. It has an important advantage in that it doesn't block the ear canal as hearing aids do. This I understand means it is far more comfortable and can been worn for longer periods and your not listening to the inside of your head or get ear problems. However, it is not applicable to all hearing problems and probably not suitable for everyone. But I cannot think that there would be any harm in suggesting that they look into it. Perhaps you can report back on how they get on. Regards, Maddox | maddox | |
11/10/2004 09:58 | Maddox, if you knew personally someone who was hard of hearing, would you recommend RetroX? How would you persuade them that it is better than a digital hearing aid? | pachiaammos | |
11/10/2004 09:55 | Maddox, if you knew personally someone who was hard of hearing, would you recommend RetroX? How would you persuade them that it is better than a digital hearing aid? | pachiaammos | |
06/10/2004 22:55 | Zapa, My understanding of RetroX is somewhat different. Basically, it is a far superior product, albeit still in the early stages of its development, it can only get better. However, its key beneit is derived by the small insertion of a titanium tube through the soft tissue into the ear canal. The minute hearing device then fits onto this, very unobtrusively, behind the ear. Due to the tube insertion a minor surgical procedure is required by a suitably qualified practitioner. Thus there is little reason to expect a bad press through poor procedures, these guys are well trained. However, the superior RetroX is competing against 'hearing aids' that can be fitted by less well qualified, more numerous, well established (and tied to the hearing aid manufacturers)distri There are thus good prospects for RetroX but not until it gets momentum. As I said I'm concentrating on the core products prospects to drive the revenue. RetroX is a future star to watch. Regards, Maddox | maddox | |
06/10/2004 20:02 | Hi guys, Managed to spend a little time looking up RetroX and came across a couple of comments.Seems when compared to Resoundair that the RetroX is a winner as it is a 'canal insertion' and therefore,once the wound has healed,invisable. But on the negative side the sales team are not up to scratch according to some.I guess as the company is small and the Yanks being more comfortable with known brands the sales of RetroX will take a little time.My problem is that there will be a delay in terms of 'field trials'ie enough out there and fitted to sort any problems before we get bad press. Any surgery after the event is not going to go down well. Thoughts? | zapa | |
06/10/2004 18:51 | BullandBear I'm a business consultant focussing on strategy, business development, research and analysis. I am also a director of a marketing services business that is taking most of my attention presently. So I'm not in the healthcare sector specifically if that what prompts your question. Its the business model,the bold business strategy and excellent execution that has attracted me to Gyrus. Regards, Maddox | maddox | |
06/10/2004 15:50 | Maddox hi mate, what do you do for a living just out of interest ? | bullandbear | |
05/10/2004 21:30 | Hi Zapa, Sorry for not replying sooner. I haven't looked in too much depth at the new product pipeline as they are just another supporting act to the headline products. The product range is getting broader and deeper all the time as further improved products or in-fill products are launched. These are now being supplemented by products in-sourced from other suppliers where GYG is acting as the distributor. The really new product lines, such as the new hearing device, absolutely fabulous product, truely innovative, will take some time to gain traction in the marketplace. Basically, this is because it is so novel that it doesn't fit neatly into the exiting distribution channels. So the prospects are good but will have little immediate impact. Overall though the transformation of Gyrus has been dramatic over the last few years - from having only a couple of products to now having, what, hundreds?!?! What I am looking for, and I think we are starting to see it, is the effect of the generator placement. As each generator starts to get used more frequently for more operations using more disposables then the revenue should start to accelerate away. When that generator base has itself increased 33% y-o-y then you can see what I'm waiting for. An aside in the last results gives a clue that this might be happening. Whereas GYG used to place the generators for free the customers are now chosing to purchase them outright. This gives them a discount against the cost of the disposables. But the key point is that this will only make financial sense if you are going to using a lot of them! Regards, Maddox | maddox | |
29/9/2004 10:06 | Thanks Maddox.Any ideas re the new products. | zapa | |
29/9/2004 09:58 | Zapa, Re. Director selling, I see nothing of particular concern here. Dr Mark Goble one of the founders, has moved back into a strategic role and is pursuing another opportunity related to Gyrus' technology in the cosmetic surgery field. My understanding is that he is funding this separately to Gyrus. It is thus not surprising that he wants to take some of his Gyrus holding out. (This linkage is my speculation - I have no firm info.) However, any director selling is unwelcome, particularly without explanation, and at the very least it puts downward pressure on the price if the quantity is large. On the other hand, I note Simon Shaw the CFO has bought £21k of shares. Regards, Maddox | maddox | |
28/9/2004 13:11 | mad, zap.. I agree with your comments.. Do you not expect this to recover though in the short term... nice stable stock will growth potential. | bullandbear | |
26/9/2004 09:17 | Thanks Maddox.Looking at the y-o-y and the news that there is going to be more new products during the coming months is a relief.Debt down to £8m is also a very positive sign.The hearing aid product will pick up when the sales team get to grips with the benefits of the product(according to one article). The director & fund manager trimming their holdings didnt help coupled with the ICs hurried article. Long term hold and buy on weakness if the wife lets me. Thanks again for your time,excuse the hurried reply(we are doing our year end)! ps. look at HCEG and their disposable endoscope. | zapa | |
25/9/2004 11:06 | No laughing now.......I just bought the IC re Gyrus and found their comments far from reassuring.As I am pushed for time these days can someone (hopefully Maddox) tell me whether sales are flat or not. Thanks. David. | zapa | |
21/9/2004 14:23 | mms collecting maybe,, this is due an upturn now.. great company and great solid stock. | bullandbear |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions